|55 Kenosia Avenue
Danbury, CT 06810
Toll Free: 1.800.999.6673
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
Copyright 1986, 1987, 1988, 1989, 1991, 1993, 1994, 1996, 1997, 1999, 2003, 2004, 2009
NORD is very grateful to Steven Scherer, MD, PhD, Department of Neurology, University of Pennsylvania and Mustafa Saifi, PhD, Department of Molecular and Human Genetics, Baylor College of Medicine, for assistance in the preparation of this report.
Charcot Marie Tooth disease is a group of disorders in which the motor and/or sensory peripheral nerves are affected, resulting in muscle weakness and atrophy, as well as sensory loss. These manifestions occur first in the distal legs and later in the hands. The nerve cells in individuals with this disorder are not able to send electrical signals properly because of abnormalities in the nerve axon or abnormalities in the insulation (myelin) around the axon. Specific gene mutations are responsible for the abnormal function of the peripheral nerves. Charcot Marie Tooth disease can be inherited in an autosomal dominant, autosomal recessive or X-linked mode of inheritance.
Symptoms of Charcot-Marie-Tooth disease usually begin gradually in adolescence, but can begin earlier or later. In almost all cases, the longest nerve fibers are affected first. Over time, affected individuals may lose the normal use of their feet, hands, legs and arms. Common red flags can include decreased sensitivity to heat, touch or pain, muscle weakness in the hand, foot or lower leg, trouble with fine motor skills, high-stepped gait (foot drop), loss of muscle mass in the lower leg, frequent tripping or falling, hammertoe, high foot arch and flat feet. Stretch reflexes may be lost. The disease is slowly progressive and variable and those affected may remain active for years and live a normal life span. In the most severe cases, breathing difficulties can hasten death.
Charcot Marie Tooth disease can be inherited in an autosomal dominant, autosomal recessive or X-linked dominant manner.
Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.
Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.
Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary for the appearance of the disease. The abnormal gene can be inherited from either parent, or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.
X-linked dominant genetic disorders are caused by an abnormal gene on the X chromosome. Females with an abnormal gene are affected with the disease. Males with an abnormal gene are more severely affected than females.
CMT hereditary neuropathy is subdivided into several types termed CMT1, CMT2, CMT3, CMT4 and CMTX.
CMT1 is the dominant form of the condition in which nerve conduction velocities are slow, and is much more common that CMT2. CMT1 is caused by abnormal genes involved in the structure and function of myelin. CMT1 has been further subdivided into CMT1A, CMT1B, CMT1C, CMT1D, and CMT1X, based on specific gene abnormalities. CMT1A is caused by a duplication of the PMP22 gene that is located on chromosome 17 at 17p11.2. CMT1A is the most common type of CMT1. CMT1B is caused by an abnormality in the MPZ gene located on chromosome 1 at 1q22. CMT1C is caused by an abnormality in the SIMPLE gene located on chromosome 16 at 16p13.1-p12.3. CMT1D is caused by an abnormality in the EGR2 gene located on chromosome 10 at 10q21.1-q22.1. CMT1X is caused by mutations in GJB1 (located at Xq13.1), the gene that encodes the gap junction protein connexin32. Rarer subtypes of CMT1 may yet be found.
CMT2 is an autosomal dominant form of the condition in which nerve conduction velocities are usually normal or slightly slower than normal. CMT2 is caused by abnormal genes involved in the structure and function of axons. CMT2 has been further subdivided into CMT2A - 2L based on mutations in specific genes. CMT2A, is the most common, and is caused by mutations in the MFN2 gene located on chromosome 1 at 1p36.2. CMT2B is caused by mutations in the RAB7 gene located on chromosome 3 at 3q21. CMT2C is caused by an unknown gene located on chromosome 12 at 12q23-34. CMT2D is caused by mutations in the GARS gene located on chromosome 7 at 7p15. CMT2E is caused by mutations in the NEFL gene located on chromosome 8 at 8p21. CMT2F is caused by mutations in the HSPB1 gene. CMT2L is caused by mutations in the HSPB8 gene.
Dominant Intermediate CMT (DI-CMT) is so named owing to their "intermediate" conduction velocities and thus an uncertainty regarding whether the neuropathy is primarily axonal or demyelinating. Dominant mutations in DMN2 and YARS are known to cause this phenotype.
CMT3, also called Dejerine-Sottas disease, is no longer a useful genetic designation because individuals with this condition have been found to have a gene mutation in one of the genes responsible for CMT1A, CMT1B, CMT1D or CMT4.
CMT4 is an autosomal recessive form of the condition. It has been further subdivided into CMT4A, CMT4B1, CMT4B2, CMT4C, CMT4D, CMT4E and CMT4F. CMT4A is caused by an abnormality in the GDAP1 gene located on chromosome 8 at 8q13-q21. CMT4B1 is caused by an abnormality in the MTMR2 gene located on chromosome 11 at 11q22. CMT4B2 is caused by an abnormality in the SBF2/MTMR13 gene located on chromosome 11 at 11p15. CMT4C is caused by an abnormality in the KIAA1985 gene located on chromosome 5 at 5q32. CMT4D is caused by an abnormality in the NDRG1 gene located on chromosome 8 at 8q24.3. CMT4E, also known as congenital hypomyelination neuropathy, is caused by an abnormality in the EGR2 gene located on chromosome 10 at 10q21.1-q22.1. CMT4F is caused by an abnormality in the PRX gene located on chromosome 19 at 19q13.1-q13.2. CMT4H is caused by an abnormality in the FDG4 gene. CMT4J is caused by an abnormality in the FIG4 gene. Most cases of CMT2 are not caused by mutations in these genes, however, so that many genetic causes remain to be discovered.
CMTX is an X-linked dominant form of the condition. CMT1X accounts for approximately 90% of CMTX. The specific gene(s) responsible for the remaining 10% of individuals with CMTX have not yet been identified.
Autosomal recessive CMT2 is caused by mutations in LMNA and GDAP1.
Symptoms of CMT hereditary neuropathy usually begin gradually sometime in adolescence, early adulthood or middle age. The condition affects an equal number of males and females. CMT hereditary neuropathy is the most common inherited neurological disorder affecting more than 250,000 Americans. Since this condition is frequently undiagnosed, misdiagnosed or diagnosed very late in life, the true number of affected persons may be higher.
In hereditary sensory and autonomic neuropathies, sensory (and variably autonomic) neurons/axons are affected, with relative or complete sparing of motor neurons/axons. Dominant and recessive mutations in neuronally expressed genes cause HSAN and related disorders. These are dominant or recessive hereditary disorders.
Hereditary motor neuropathies are either dominantly or recessively inherited. In most forms, sensory fibers are spared, and some kinds are associated with a myelopathy.
Hereditary neuralgic amyotrophy (inherited brachial plexus neuropathy) is an autosomal dominant genetic disorder in which those affected have a sudden onset of pain or weakness in the shoulder or upper arm. Symptoms often begin in childhood but can begin at any age. Sensory loss may also occur. Partial or full recovery is common and symptoms can recur in the same or opposite limb. Physical features that have been noted in some families, including short stature and close-set eyes.
Congenital hypomyelination neuropathy (CHN) is a neurological disorder present at birth. Major symptoms may include respiratory difficulty, muscle weakness and incoordination, poor muscle tone, absence of reflexes, difficulty in walking, and/or impaired abilities to feel or move part of the body. (For more information, choose "neuropathy, congenital hypomyelination" as your search term in the Rare Disease Database).
Refsum syndrome (phytanic acid storage disease) is a rare recessive genetic disorder of fat (lipid) metabolism characterized by peripheral neuropathy, impaired muscle coordination (ataxia), retinitis pigmentosa (RP), deafness, and bone and skin changes. It is associated with marked accumulation of phytanic acid in the blood plasma and tissues. The disorder may be due to the absence of phytanic acid hydroxylase, an enzyme needed for the metabolism of phytanic acid. Prolonged treatment with a diet lacking in phytanic acid may be therapeutic. (For more information, choose "Refsum" and "RP" as your search terms in the Rare Disease Database.)
Familial amyloid neuropathy has autosomal dominant inheritance. It is characterized by abnormal accumulations of amyloid in the peripheral nerves. Most cases are caused by mutation in the TTR gene, which encodes the serum protein transthyretin. Dominant mutations in APOA1 are a rare cause.
Hereditary neuropathy with liability to pressure palsy (HNPP) is rare disorder that follows autosomal dominant inheritance. HNPP is characterized by focal neuropathies at typical sites of compression (peroneal neuropathy at the fibular head, ulnar neuropathy at the elbow, median neuropathy at the wrist). HNPP is caused by an abnormality in one of the two copies of PMP22 gene located on chromosome 17 at 17p11.2.
Peripheral neuropathy is part of at least 100 inherited syndromes, though it is typically overshadowed by the other manifestations. Nevertheless, de/dysmyelination of peripheral axons is a feature of a variety of disorders. Syndromes associated with axonal neuropathies are even more common. Several types of hereditary spastic paraglegias have an axonal neuropathy, involving both motor and sensory axons or just motor axons. An axonal neuropathy is a feature of many hereditary ataxias. The clinical phenotypes are consistent with the idea that these diseases are length-dependent axonopathies of both CNS and PNS neurons.
The diagnosis of CMT hereditary neuropathy can be challenging. The diagnosis is based on physical symptoms, family history and clinical tests. Clinical tests include nerve conduction velocity (NCV) which measures the speed at which impulses travel along the nerves and electromyogram (EMG) which records the electrical activity of muscle cells Molecular genetic testing is currently available for CMT1A, CMT1B, CMT1D, CMT2E, CMT4A, CMT4E, CMT4F and CMTX.
Treatment of CMT hereditary neuropathy is symptomatic and supportive. A cure is not available so it is important to minimize or stall the symptoms. Comprehensive treatments include physical therapy, shoe orthotics, leg braces and surgery to correct deformities. Complementary therapies may help psychologically, relieve pain and discomfort, and improve overall quality of life. Vocational counseling, anticipating progression of the disorder, may be useful for young patients.
Research is ongoing into possible new therapies for CMT hereditary neuropathy. For the most current information, please contact the agencies listed in the Resources section of this report.
A Focused Study of Certain Genetic Diseases: Studies are underway to learn more about certain genetic (neuromuscular and non-neuromuscular) diseases. Blood samples will be used to extract DNA samples for study. Charcot Marie Tooth disease is one of the disorders being studied. For more information on these studies, please contact:
Association Francaise Contre Les Myopathies
1 Rue De L'Internationale
BP 59 - 91002
Evry CEDEX, Nancy
Phone: 011 33 88 1 69 47 28 28
Fax: 011 33 88 60 77 12 16
A clinical study of Charcot Marie Tooth hereditary neuropathy is being conducted at Wayne State University in Michigan. This study will help researchers to better understand the progression and natural history of CMT and related conditions so new treatments can be evaluated in future clinical trials. For more information, contact Lisa Rowe at (313) 577-1689.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
University of Chicago
5841 South Maryland Ave, MC 2030
Chicago, IL 60637
Phone #: 773-702-5659
800 #: N/A
Home page: http://peripheralneuropathycenter.uchicago.edu/
PO Box 105
Glenolden, PA 19036
Phone #: 610-499-9264
800 #: 800-606-2682
Home page: http://www.charcot-marie-tooth.org
201 Chicago Ave, #200
Minneapolis, MN 55415 USA
Phone #: 952-641-6100
800 #: 877-263-5430
Home page: http://www.childneurologyfoundation.org
PO Box 8126
Gaithersburg, MD 20898-8126
Phone #: 301-251-4925
800 #: 888-205-2311
Home page: http://rarediseases.info.nih.gov/GARD/
432 Park Avenue South, 4th Floor
New York, NY 10128
Phone #: 212-722-8396
800 #: 855-435-7268
Home page: http://www.hnf-cure.org
1900 University Avenue, Suite 101
East Palo Alto, CA 94303
Phone #: 650-462-3174
800 #: N/A
Home page: http://www.letthemhear.org
PO Box 241956
Los Angeles, CA 90024
Phone #: 310-264-0826
800 #: N/A
Home page: http://www.madisonsfoundation.org
3300 East Sunrise Drive
Tucson, AZ 85718-3208 USA
Phone #: 520-529-2000
800 #: 800-572-1717
Home page: http://www.mda.org/
P.O. Box 5801
Bethesda, MD 20824
Phone #: 301-496-5751
800 #: 800-352-9424
Home page: http://www.ninds.nih.gov/
2305 Kitty Hawk Dr
Plano, TX 75025
Phone #: 214-435-8288
800 #: N/A
Home page: http://www.ptlsfoundation.org
Shy ME, Lupski JR, Chance PF, Klein CJ, Dyck PJ (2005) Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features. In: Peripheral Neuropathy, 4th Edition (Dyck PJ, Thomas PK, eds), pp 1623-1658. Philadelphia: Saunders.
Wrabetz L, Feltri ML, Kleopa KA, Scherer SS (2004) Inherited neuropathies: clinical, genetic, and biological features. In: Myelin Biology and Disorders (Lazzarini RA, ed), pp 905-951. San Diego: Elsevier Academic Press.
Saifi GM, Szigeti K, Snipes GJ, Garcia CA, Lupski JR. Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for charcot-marie-tooth disease and related peripheral neuropathies. J Invest Med 2003;51:261-83.
Irobi J, DeJonghe P, Timmerman V (2004) Molecular genetics of distal hereditary motor neuropathies. Hum Mol Genet 13:R195-R202.
Scherer SS (2006) Finding the causes of inherited neuropathies. Arch Neurol 63:812-816.
FROM THE INTERNET
Online Mendelian Inheritance in Man (OMIM): http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim
Report last updated: 2009/04/03 00:00:00 GMT+0